View Single Post
Old 02-19-2007, 06:49 PM   #1
eric
Senior Member
 
Join Date: Sep 2005
Posts: 589
Taxotere and JMR-132

http://news.yahoo.com/s/afp/20070130...ushealthcancer

Combination therapy promising for breast cancer: Study

CHICAGO (AFP) - An experimental new treatment for breast cancer can dramatically shrink, and in some cases, eliminate, tumors in mice that have been infected with the disease, a study has said. <SCRIPT language=javascript>if(window.yzq_d==null)window.y zq_d=new Object();window.yzq_d['ipGHBdGDJHQ-']='&U=13b5fr6u1%2fN%3dipGHBdGDJHQ-%2fC%3d571699.10029817.10887929.1442997%2fD%3dLREC %2fB%3d4368327';</SCRIPT><NOSCRIPT></NOSCRIPT>
The new therapy involves a combination of a chemotherapy drug, Taxotere (generic name: docetaxel) and a novel compound called JMR-132, that starves the tumor of growth-stimulating hormone. The compound binds to receptors on the tumor, and in so doing blocks the release of the growth hormone.

Tested separately, the drug and the growth factor inhibitor were extremely effective at shrinking the tumors in mice infected with a hard-to-treat, estrogen-independent form of breast cancer.

On its own, the Taxotere reduced the volume of the mice tumors by an average of 74 percent in three weeks. In mice treated with JMR-132, the volume reduction was 63 percent.

Together, the two therapies reduced the volume of the cancerous cells by more than 97 percent. In some cases, when the researchers examined the dead mice, they could not find any cancer cells at all.

What's more, the treatment did not appear to be toxic or trigger any other major side effects in the animals, suggesting it might be well-tolerated in humans, the researchers said.
eric is offline   Reply With Quote